BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
| العنوان: | BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset? |
|---|---|
| المؤلفون: | Jeanne Tie, Jayesh Desai, Simone Steel, Vanessa Wong, Jeremy Shapiro, Margaret Lee, Peter Gibbs, Adnan Khattak, Rachel Wong, Wei Hong, Matthew Burge, Brigette B.Y. Ma, Louise M. Nott |
| المصدر: | Targeted Oncology. 16:227-236 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, Colorectal cancer, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Overall survival, Initial treatment, Pharmacology (medical), Epidermal growth factor receptor, Splenic flexure, Chemotherapy, biology, business.industry, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, business, medicine.drug |
| الوصف: | B-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS) primaries. In metastatic CRC (mCRC), there is substantial overlap between the reported features of BRAFmt and of an RS primary. To explore the significance of BRAFmt in a left-side (LS) primary, we analysed data from a multi-site mCRC registry. Tumours distal to the splenic flexure were considered LS. Of 3380 patients enrolled from June 2009 to June 2020, 214 (13%) of 1657 with known status were BRAFmt: 127 (24%) of 524 RS and 87 (8%) of 1133 LS. LS versus RS BRAFmt were younger (mean 59.5 vs. 65.1 years; p = 0.01), whereas sex (48 vs. 59% female; p = 0.13), mismatch repair-deficiency (dMMR) (16 vs. 21%; p = 0.47), and overall survival (OS) (median 15.1 vs. 17.7 months; p = 0.98) were similar. LS BRAFmt versus LS BRAF wildtype (wt) were of similar age (59.5 vs. 61.3 years; p = 0.28) with more females (48 vs. 37%; p = 0.04), more dMMR (16 vs. 1%; p < 0.0001), and inferior OS (median 15.1 vs. 36.6 months; p < 0.0001). Initial treatment with chemotherapy plus an epidermal growth factor receptor inhibitor produced median progression-free survival (PFS) of 4.3 versus 12.3 months (p = 0.20) for LS BRAFmt (n = 9) versus LS BRAFwt (n = 104). Initial chemotherapy and bevacizumab produced a median PFS of 7.6 versus 11.6 months (p = 0.02) for LS BRAFmt (n = 36) versus LS BRAFwt (n = 438), respectively. LS BRAFmt cancers share many features with RS BRAFmt cancers, including poor survival outcomes. Mature data on the activity of BRAF-targeted therapies in the first-line setting are eagerly awaited. |
| تدمد: | 1776-260X 1776-2596 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::22f7d7e129140a629988bd9957af1d94Test https://doi.org/10.1007/s11523-021-00793-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........22f7d7e129140a629988bd9957af1d94 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1776260X 17762596 |
|---|